Pfizer Inc PFE

$27.50 +0.09 (0.33%)

Valuation

Market cap
158,450,928,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.22
Forward PE
9.45
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
24,066,072
Avg volume
36,119,434
Day's range
$27.20 – $27.71
Shares out
5,699,674,000
Stochastic %K
16%
Beta
0.32
Analysts
Sell
Price target
$28.95

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

TradeverythingforGod Oct 6, 11:30 PM
$PFE How about +5%
0 replies
CashMoneyGreen Oct 6, 11:15 PM
$PFE run to 35
0 replies
nimii Oct 6, 7:45 PM
$PFE russian plague 🦠💰
0 replies
zustrelaax Oct 6, 7:28 PM
$PFE $NVAX power hour , AH to be watched given the news
0 replies
zustrelaax Oct 6, 5:20 PM
$PFE only trump PR can move this
1 replies
STOCKPICKERTRADER Oct 6, 5:03 PM
$PFE even upgrades and price target increases no help today.... Scotiabank Adjusts Pfizer Price Target to $33 From $30, Sector Outperform Rating Kept MT NEWSWIRES Oct-06-2026 12:31 p.m. ET 12:31 PM EDT, 10/06/2026 (MT Newswires) -- Pfizer (PFE) has an average rating of hold and mean price target of $28.61, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
1 replies
STOCKPICKERTRADER Oct 6, 4:27 PM
$PFE grinder
0 replies
SuperGreenToday Oct 6, 3:43 PM
$PFE Share Price: $27.57 Contract Selected: Oct 30, 2026 $30 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.08 – $0.10 Potential Upside: 75% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 replies